Prion diseases are a type of infectious disease transmitted by a self-replicating protein, the prion protein (PrP), and as yet are still not fully understood at the molecular level.
Cellular and molecular evidence of prion-like propagation in neurodegenerative diseases, the clinical relevance of their cell-to-cell propagation by 'seeding' capacities, and their levels of contribution towards disease progression have been intensively studied over recent years. These studies discuss the cyclic prion-like propagation in cells including factors of aggregate internalization, endo-lysosomal leaking, aggregate degradation, and secretion. 1
Debates on the importance of the role of prion-like protein aggregates in neurodegenerative diseases (ND) and whether they are causal or a consequence of the disease, are also discussed.1
The accumulation and spread of prion-like proteins is a key feature of neurodegenerative diseases (NDs) such as Alzheimer's disease, Parkinson's disease, or Amyotrophic Lateral Sclerosis. In a process known as 'seeding', prion-like proteins such as alpha Synuclein, propagate their misfolded configuration by transforming their respective soluble monomers into fibrils. 1
Parkinson's disease (PD) is characterized by the presence of alpha Synuclein inclusions in the brain and the degeneration of dopamine-producing neurons. There is evidence to suggest that the progression of PD may be due to the prion-like spread of alpha Synuclein a protein related to the pathology of Parkinson's disease, that shows many prion-like pathogenic characteristics. 2 So understanding and limiting alpha Synuclein propagation has become a key area of research for developing novel PD treatments. 3
Significant evidence suggests that misfolded alpha-synuclein (aSyn), a major component of Lewy bodies, propagates in a prion-like manner contributing to disease progression in Parkinson's disease (PD) and other synucleinopathies. In fact, inoculation of mice with human alpha Synuclein preformed fibrils (PFF) has promoted Parkinson-like symptoms and deficits in these mice associated with substantial spreading of pathogenic alpha-synuclein.8
Lewy bodies are round, reddish inclusions inside the body of the nerve cell and composed of an abnormally folded and aggregated protein called alpha-synuclein.
Alpha-synuclein is a 140-amino-acid protein divided into three regions with distinct net charges. 4
alpha Synuclein also has a high propensity to aggregate to β-rich structures in a complex sequence of events which involves soluble oligomers and insoluble fibrils. 5
Under pathological conditions alpha Synuclein monomers become misfolded and form insoluble, fibrils as well as neurotoxic oligomeric intermediates. 4
As a monomer, the protein is intrinsically disordered and only forms organized structure when it binds to other partners. Although its “true” function is unclear, it is linked to membranes by its association with synaptic trafficking and forms α-helical structures on membranes. 5
Certainly, alpha Synuclein aggregation may not be the sole cause of dopaminergic neuronal loss, and our understanding of the complex interactions between the aggregates of pathogenic proteins and neurodegeneration continues to evolve. 6
Although Lewy Body pathology is not the only causative factor for PD, it is known that in the presence of alpha Synuclein oligomers and fibrils, neurodegeneration occurs.6
PD and Dementia Lewy Body share a similar pathological hallmark of alpha Synuclein aggregates throughout the nervous system including in the limbic, brainstem, and cortical regions of the brain. 7
Although alpha Synuclein aggregation is seen as a unifying and “central pathological change”, the complexity of these processes may be appreciated by the fact that different synucleinopathies show different clinical symptoms and affect different brain cells (neurons or oligodendroglia), leading to different types of intracellular aggregates (spherical Lewy bodies in PD, less structured glial cytoplasmic alpha Synuclein inclusions in Multiple System Atrophy). 5
Thus in practice there is a pathophysiological disease spectrum.
Even within PD itself, the disease can originate in different places, either brain-first (from which it can spread to the rest of the body) or body-first (where alpha Synuclein aggregation starts in the gut and then transmits via the vagus nerve to the brain).5
The accumulation of pathological substrates like alpha Synuclein can precede the clinical onset of symptoms in patients by decades. Therefore, the early detection of misfolded protein accumulation may be used to facilitate a more timely diagnosis and more effective treatment.5
A significant reduction in alpha Synuclein aggregations with a corresponding increased preservation in dopaminergic innervation observed from in vivo (animal) studies, indicate a clear benefit of targeting alpha Synuclein in preventing the progression of PD. Similarly, the positive outcomes from the clinical studies assessing the efficacy and safety of immunotherapies provide evidence of the potential viability of anti- alpha Synuclein therapies. 6
Therefore, treatments that target alpha Synuclein oligomeric and/or fibrillar species that are toxic to neurons may reduce neurodegeneration, but this therapeutic strategy has yet to be fully translated into efficacious clinical studies. 6
Even as human clinical studies of targeting alpha Synuclein lag, the evidence available on the effect of a therapy aimed at oligomeric and fibrillar alpha Synuclein and its interaction with dopaminergic neuronal activity suggest that alpha Synuclein should be a primary target to suppress neurodegeneration in Parkinson’s Disease. Taken together the data in this review, provides compelling evidence that alpha Synuclein is a viable and promising target to limit alpha Synuclein contribution to the development and progression of PD. 6
Exposure of cell to preformed recombinant alpha Synuclein fibrils induces the formation of visible aggregations within these cells, which could be characterized by using four indices: 1. The number of dots per cell, 2. The size of dots, 3. The intensity of dots, and 4. The percentage of cells containing alpha Synuclein aggregations. The four indices proved to be reliable indicators of the effectiveness of interventions and therapeutic agents directed against alpha Synuclein propagation in a treatment screening model.
This simple and efficient in vitro model system can be used for high-throughput screening to discover novel therapies for inhibiting alpha Synuclein spread.3
A recent technique, the seeding amplification assay (SAA) is able to detect minute amounts of misfolded αSyn in the cerebrospinal fluid (CSF) by examining its ability to induce further aggregation of non-aggregated or monomeric alpha Synuclein.7
This alpha Synuclein Seeding Amplification Assay CSF biomarker was able to detect alpha Synuclein in CSF of confirmed D-Lewy Body and Parkinson’s Disease patients with a sensitivity of 92% and 95%, respectively, and a 100% specificity.7
These assays are also able to detect the accumulation of misfolded alpha Synuclein in subjects with features of prodromal parkinsonism, such as isolated rapid eye movement (REM) sleep behavior disorder (IRBD) and pure autonomic failure.7 A positive result of alpha Synuclein Seeding Amplification Assay in IRBD cases was associated with an increased risk of developing PD and DLB at 2, 4, 6, 8, and 10 years of follow-up.7
References
1.Hu C, Yan Y, Jin Y, Yang J, Xi Y, Zhong Z. Decoding the Cellular Trafficking of Prion-like Proteins in Neurodegenerative Diseases. Neurosci Bull. Published online September 27, 2023. doi:10.1007/s12264-023-01115-9
2.Cordeiro Y, Freire MHO, Wiecikowski AF, do Amaral MJ. (Dys)functional insights into nucleic acids and RNA-binding proteins modulation of the prion protein and α-synuclein phase separation. Biophys Rev. 2023;15(4):577-589. doi:10.1007/s12551-023-01067-4
3.Kim BJ, Noh HR, Jeon H, Park SM. Monitoring α-synuclein Aggregation Induced by Preformed α-synuclein Fibrils in an In Vitro Model System. Exp Neurobiol. 2023;32(3):147-156. doi:10.5607/en23007
4.Kamski-Hennekam ER, Huang J, Ahmed R, Melacini G. Toward a molecular mechanism for the interaction of ATP with alpha-synuclein. Chem Sci. 2023;14(36):9933-9942. doi:10.1039/d3sc03612j
5.Vasilevskaya A, Martinez-Valbuena I, Anastassiadis C, et al. Misfolded α-Synuclein in Cerebrospinal Fluid of Contact Sport Athletes. Mov Disord Off J Mov Disord Soc. Published online October 4, 2023. doi:10.1002/mds.29621
6.Rodger AT, ALNasser M, Carter WG. Are Therapies That Target α-Synuclein Effective at Halting Parkinson’s Disease Progression? A Systematic Review. Int J Mol Sci. 2023;24(13):11022. doi:10.3390/ijms241311022
7.Peña-Bautista C, Kumar R, Baquero M, et al. Misfolded alpha-synuclein detection by RT-QuIC in dementia with lewy bodies: a systematic review and meta-analysis. Front Mol Biosci. 2023;10:1193458. doi:10.3389/fmolb.2023.1193458
8.Tullo S, Miranda AS, Del Cid-Pellitero E, et al. Neuroanatomical and cognitive biomarkers of alpha-synuclein propagation in a mouse model of synucleinopathy prior to onset of motor symptoms. J Neurochem. Published online October 7, 2023. doi:10.1111/jnc.1596